SCHEMBL4498039

SCHEMBL4498039

CCNCc1ccc(N/C(=C2\C(=O)Nc3cc(F)ccc32)c2ccc(N3CCOC3=O)cc2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELOVL6 Q9H5J4 1/20 0.37
KDM1A O60341 4/20 0.36
MAOA P21397 4/20 0.36
MAOB P27338 4/20 0.36
RCOR1 Q9UKL0 4/20 0.36
NAMPT P43490 1/20 0.34
BACE1 P56817 1/20 0.33
METAP2 P50579 1/20 0.33
CHEK1 O14757 2/20 0.32
MAPK1 P28482 2/20 0.32
CHEK2 O96017 1/20 0.32
KIT P10721 1/20 0.32
MARK3 P27448 1/20 0.32
AKT1 P31749 1/20 0.32
MARK2 Q7KZI7 1/20 0.32
AURKB Q96GD4 1/20 0.32
ATM Q13315 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
TTK P33981 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4498045 1.00 ELOVL6 (0.37) ELOVL6KDM1AMAOAMAOBRCOR1
SCHEMBL4484130 0.91 KDM1A (0.36) KDM1AMAOAMAOBRCOR1CHEK1
SCHEMBL4484127 0.91 KDM1A (0.36) KDM1AMAOAMAOBRCOR1CHEK1
SCHEMBL4483327 0.88 ELOVL6 (0.37) ELOVL6KDM1AMAOAMAOBRCOR1
SCHEMBL4483330 0.88 ELOVL6 (0.37) ELOVL6KDM1AMAOAMAOBRCOR1
SCHEMBL4483325 0.85 KDM1A (0.41) ELOVL6KDM1AMAOAMAOBRCOR1
SCHEMBL3933227 0.83 MAOB (0.43) MAOBNAMPTBACE1MAPK1MEN1
SCHEMBL3933238 0.83 MAOB (0.43) MAOBNAMPTBACE1MAPK1MEN1
SCHEMBL4492562 0.82 ELOVL6 (0.37) ELOVL6KDM1AMAOAMAOBRCOR1
SCHEMBL4492558 0.82 ELOVL6 (0.37) ELOVL6KDM1AMAOAMAOBRCOR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR ELOVL6 2925/4885KDM1A 1808/4885MAOA 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.